BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Reference Citation Analysis]
2 Elston DM. Hepatitis B reactivation in patients on biologics: A perfect storm. J Am Acad Dermatol 2020:S0190-9622(20)32590-1. [PMID: 33048666 DOI: 10.1016/j.jaad.2020.09.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Edens C. The Impact of Pediatric Rheumatic Diseases on Sexual Health, Family Planning, and Pregnancy. Rheum Dis Clin North Am 2022;48:113-40. [PMID: 34798942 DOI: 10.1016/j.rdc.2021.09.016] [Reference Citation Analysis]
4 Aguirre A, Yazdany J. Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. J Rheumatol 2022;49:1-4. [PMID: 34725177 DOI: 10.3899/jrheum.211000] [Reference Citation Analysis]
5 Zhou Q, Zhang Q, Wang K, Huang T, Deng S, Wang Y, Cheng C. Anti-rheumatic Drug-induced Hepatitis B Virus Reactivation and Preventive Strategies for Hepatocellular Carcinoma. Pharmacol Res 2022;:106181. [PMID: 35301112 DOI: 10.1016/j.phrs.2022.106181] [Reference Citation Analysis]
6 Kiltz U, Celik A, Tsiami S, Buehring B, Baraliakos X, Andreica I, Kiefer D, Braun J. Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study. RMD Open 2021;7:e001499. [PMID: 33832974 DOI: 10.1136/rmdopen-2020-001499] [Reference Citation Analysis]
7 Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021;. [PMID: 33387124 DOI: 10.1007/s10620-020-06725-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kridin M, Zloto O, Kridin K, Cohen AD, Mann O, Weinstein O. The association of uveitis with hepatitis B and hepatitis C viruses: a large-scale population-based study. Eye (Lond) 2022. [PMID: 35352013 DOI: 10.1038/s41433-022-02037-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Thomas K, Vassilopoulos D. Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies. Mediterr J Rheumatol 2020;31:129-36. [PMID: 32676571 DOI: 10.31138/mjr.31.1.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med 2021;10:2564. [PMID: 34200522 DOI: 10.3390/jcm10122564] [Reference Citation Analysis]
11 Kłujszo EH, Zarębska-Michaluk D, Kręcisz B, Witkowska A. Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection. Dermatol Ther 2021;:e15274. [PMID: 34921578 DOI: 10.1111/dth.15274] [Reference Citation Analysis]
12 Maramattom BV, Syed AA. Viral neuromyopathy associated with acute hepatitis B infection. BMJ Case Rep 2022;15:e247203. [PMID: 34980642 DOI: 10.1136/bcr-2021-247203] [Reference Citation Analysis]